# Extension Study Evaluating Long Term Safety and Activity of AGT-181 in Children With MPS I

> **NCT03071341** · PHASE1,PHASE2 · COMPLETED · sponsor: **ArmaGen, Inc** · enrollment: 19 (actual)

## Conditions studied

- Mucopolysaccharidosis I

## Interventions

- **DRUG:** AGT-181

## Key facts

- **NCT ID:** NCT03071341
- **Lead sponsor:** ArmaGen, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10
- **Primary completion:** 2018-02-01
- **Final completion:** 2018-02-01
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2023-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03071341

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03071341, "Extension Study Evaluating Long Term Safety and Activity of AGT-181 in Children With MPS I". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03071341. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*